MWX-203
/ Minwei Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 05, 2026
MWX203-II-DLP: Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia
(clinicaltrials.gov)
- P2 | N=216 | Recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd
New P2 trial • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia • APOB
September 03, 2026
Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=54 | Active, not recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd
New P1 trial
1 to 2
Of
2
Go to page
1